Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

S in the U.S.  In March 2013, BDSI and its commercial partner Meda submitted a proposal to FDA to reintroduce ONSOLIS for the treatment of breakthrough cancer pain into the U.S. marketplace following previously reported appearance issues with the product.  If approved by FDA, the original ONSOLIS formulation may be on the market during the second-half of 2013 while stability data is collected on a newly formulated version of ONSOLIS.  These data may be submitted to FDA before the end of the year, and if approved, could allow introduction of the new formulation sometime in 2014.  
  • Exploration of potential new products and technologies.  In addition to advancing its lead products in development, BDSI is also, as in the past, exploring the application of its BEMA drug delivery technology to additional pharmaceuticals.  In addition, BDSI continues to investigate potential new products and technologies to complement and diversify its existing portfolio. 
  • About BioDelivery Sciences International

    BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

    BDSI's pain franchise currently consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  Th
    '/>"/>

    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
    2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
    3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
    4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
    5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
    6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
    7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
    8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
    9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Service™
    10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
    11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 28, 2014 According to a ... Research "Regenerative Medicine (Bone and Joint) Market (By ... Engineering; By Applications - Bone Graft Substitutes, Osteoarticular ... Global Industry Analysis, Size, Share, Growth, Trends and ... (bone and joint) market was valued at USD ...
    (Date:7/28/2014)... /PRNewswire/ -   JOLT , a leading technology accelerator, ... its growing portfolio of startups. Next-level tech and boundary-pushing ... JOLT accelerator, and Cohort four is no exception, ... Since its launch in July 2012, JOLT has ... financing. Now at 23 investments, JOLT,s portfolio has an ...
    (Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
    (Date:7/28/2014)... It’s a hard truth: Nearly half of recent veterans who ... are failing to obtain a diploma or certificate within a ... an analysis by The Resume Place , a major ... college majors, which leads to underemployment, unemployment or just plain ... of post-9/11 veterans using GI Bill education benefits ...
    Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4
    ... TRIANGLE PARK, N.C., Jan. 24 Quintiles,Transnational Corp. ... investor partnership to support the company,s continued,growth under ... CEO Dennis,Gillings, CBE, and the management team. Gillings ... Capital have become the lead,investors in Quintiles, with ...
    ... BOHEMIA, N.Y., Jan. 23 NBTY, Inc. (NYSE: NTY ... nutritional,supplements, today announced it will web cast a conference call ... http://www.nbty.com on,Monday, January 28, 2008 at 8:30 AM ... will be issued at 7:00 AM (ET) that,day., A ...
    ... PPD, Inc. (Nasdaq:,PPDI) today announced that it ... through an exclusive agreement with Peking Union Lawke,Biomedical ... begin,immediately providing biopharmaceutical clients with its full range ... "Chinese law makes it extremely difficult to export ...
    Cached Biology Technology:Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3NBTY to Web Cast Fiscal First Quarter Conference Call 2PPD Expands Global Central Lab Services into China 2PPD Expands Global Central Lab Services into China 3
    (Date:7/27/2014)... N.C. -- Microorganisms like bacteria and fungi can evade ... antibiotics or antifungal drugs. These permanent mutations were once ... to evolve. Now a new study has shown that ... -- known as epimutations -- to gain the benefits ... new mechanism was discovered in a fungus called Mucor ...
    (Date:7/27/2014)... Institute have found that targeting a molecule in blood ... to research published in Nature today (Sunday)., ... Mary University of London, have found that a molecule, ... repair itself after chemotherapy or radiotherapy, which kill cancer ... from blood vessels that grew in melanoma or lung ...
    (Date:7/27/2014)... 18,000 patients, scientists have identified more than two ... including six that had not been previously reported. ... was partially funded by the National Institutes of ... NIH laboratories. , "Unraveling the genetic underpinnings of ... involved in this complex disease, and hopefully, may ...
    Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
    ... , Construction of ENJOY: A Generation House, the U.S. Department ... a collaborative effort of Rutgers, The State University of New ... following a recent ground-breaking at NJIT. Once construction of ... topping-off event at NJIT with major sponsors and VIP guests. ...
    ... (Boston) Kenneth Walsh, PhD, FAHA, the Aram ... of the Whitaker Cardiovascular Institute at Boston University ... 2011 American Heart Association (AHA) Distinguished Scientist. The ... The AHA created a Distinguished Scientist designation ...
    ... University biologists identified a new way in which bacteria hijack ... new antibiotics. Zhao-Qing Luo, the associate professor of biological ... new enzyme used by the bacterium Legionella pneumophila ... cell in order to take up residence. "Legionnaires, disease ...
    Cached Biology News:Team New Jersey to make precast concrete solar house reality 2BUSM professor selected as American Heart Association Distinguished Scientist 2Purdue biologists identify new strategy used by bacteria during infection 2Purdue biologists identify new strategy used by bacteria during infection 3
    ...
    Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
    Rab1A...
    ... ( Abpromise for all tested ... Synthetic peptide: DWLCL AFVE SKFNISKINE NADGSFDYGL ... amino acids 46-100 of Human LYZL6 ... 57151 Swiss ...
    Biology Products: